Hyperkalemia
USMLE Step 1 trap: Misidentifies QRS widening as the earliest ECG change in hyperkalemia rather than peaked T waves. The earliest ECG change in hyperkalemia is peaked (tall, narrow, symmetric) T waves; QRS widening occurs later as potassium rises further.
Hyperkalemia is one of the highest-yield topics on USMLE Step 1 because it hits three testable domains at once: physiology (what shifts K+ in and out of cells), pathology (which diseases impair excretion), and emergency management (ordered, mechanistic steps). The exam tests this from multiple angles — sometimes a vignette gives you ECG findings and asks what's happening, sometimes it gives you a clinical scenario (CKD, ACE inhibitor use, crush injury) and asks what treatment does mechanistically. You need to own all three layers.
From real student decks
59%have cards covering this topic
41%have mature cards
Common misconceptions
Common mistake
Wrong: The first ECG change in hyperkalemia is a widened QRS complex.
Right: The earliest ECG change in hyperkalemia is peaked (tall, narrow, symmetric) T waves; QRS widening occurs later as potassium rises further.
QRS widening is a late and dangerous sign, but it's not first. The earliest ECG change is peaked T waves — tall, narrow, and symmetric — reflecting altered ventricular repolarization even at modest potassium elevations. The sequence matters on USMLE Step 1: peaked T waves → PR prolongation → widened QRS → sine wave → V-fib. If a question asks what you'd see first on the ECG, peaked T waves is the answer every time.
Common mistake
Wrong: Calcium gluconate lowers serum potassium levels in hyperkalemia.
Right: Calcium gluconate stabilizes the cardiac membrane by raising the action potential threshold but does not lower serum potassium; it buys time while other agents shift or remove potassium.
Calcium gluconate does not touch serum potassium levels at all. It works by raising the threshold potential of cardiac myocytes, making the membrane less excitable and reducing the risk of fatal arrhythmia. Think of it as buying 30-60 minutes of cardiac protection while you do the actual work of shifting and removing potassium. Confusing stabilization with elimination is a classic trap on this exam.
Common mistake
Wrong: Insulin is given in hyperkalemia to promote renal potassium excretion.
Right: Insulin (with dextrose to prevent hypoglycemia) drives potassium into cells via Na/K-ATPase stimulation, providing a temporary transcellular shift rather than actual potassium removal.
Insulin's role in hyperkalemia is entirely intracellular — it stimulates Na/K-ATPase, driving K+ into cells and transiently lowering serum levels. It does not increase renal excretion. Because insulin will drop blood glucose, dextrose is always co-administered unless the patient is already hyperglycemic. This is a shift strategy, not a removal strategy — the potassium is still in the body.
Common mistake
Wrong: Acidosis causes hypokalemia by driving potassium into cells.
Right: Acidosis causes hyperkalemia by driving potassium out of cells in exchange for hydrogen ions moving intracellularly to buffer the acid load.
The direction here is intuitive if you think about what the body is trying to do: in acidosis, excess H+ ions move into cells to be buffered, and K+ moves out to maintain electrical neutrality. The result is hyperkalemia, not hypokalemia. The reverse is also true — alkalosis drives K+ into cells and can cause hypokalemia. This bidirectional relationship between pH and potassium is a high-yield concept that USMLE Step 1 loves to test in both directions.
What the exam tests
- Distinguish between two mechanisms causing hyperkalemia: impaired renal excretion (CKD, hypoaldosteronism, K+-sparing diuretics, ACE inhibitors) versus transcellular shifts out of cells (acidosis, insulin deficiency, beta-blockade, cell lysis in rhabdomyolysis or hemolysis).
- Identify the progressive sequence of ECG changes as serum potassium rises — from earliest (peaked T waves) through PR prolongation, widened QRS, and eventually sine wave pattern and ventricular fibrillation.
- Apply the three-step management framework in order: first stabilize the cardiac membrane (calcium gluconate), then shift potassium into cells (insulin + dextrose, albuterol, sodium bicarbonate in acidosis), then eliminate potassium from the body (loop diuretics, kayexalate, dialysis).
Can you avoid these mistakes?
A patient with end-stage renal disease presents with weakness. Their ECG shows tall, narrow, symmetric T waves with a normal QRS. What is the serum potassium likely doing, and what is the next step in management?
You give a hyperkalemic patient calcium gluconate. Thirty minutes later, the repeat potassium level is unchanged. Did the calcium gluconate fail? Explain its mechanism and what you still need to do.
A patient with diabetic ketoacidosis has a serum potassium of 5.8 mEq/L on admission. After you start insulin and IV fluids, the potassium drops to 3.1 mEq/L. What physiologic mechanism explains this rapid change?
Rank the following hyperkalemia treatments by whether they stabilize the membrane, shift potassium intracellularly, or remove potassium from the body: calcium gluconate, furosemide, albuterol, sodium polystyrene sulfonate (Kayexalate), insulin + dextrose.
Related topics
See how your Anki deck covers this topic.
Upload your deck for a free audit →